These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Systemic methotrexate therapy for psoriasis: past, present and future. Dogra S; Mahajan R Clin Exp Dermatol; 2013 Aug; 38(6):573-88. PubMed ID: 23837932 [TBL] [Abstract][Full Text] [Related]
23. Preliminary study of the efficacy and tolerability of combination therapy with calcipotriene ointment 0.005% and tacrolimus ointment 0.1% in the treatment of stable plaque psoriasis. Tirado-Sánchez A; Ponce-Olivera RM Cutis; 2012 Sep; 90(3):140-4. PubMed ID: 23094314 [TBL] [Abstract][Full Text] [Related]
24. Tacrolimus ointment is effective for facial and intertriginous psoriasis. Lebwohl M; Freeman AK; Chapman MS; Feldman SR; Hartle JE; Henning A; J Am Acad Dermatol; 2004 Nov; 51(5):723-30. PubMed ID: 15523350 [TBL] [Abstract][Full Text] [Related]
25. Pemphigus vulgaris with plaque-type psoriasis successfully treated with cyclosporine monotherapy. Rallis E; Stavropoulos P; Christofidou E; Rigopoulos D; Koumantaki-Mathioudaki E Am J Clin Dermatol; 2011 Aug; 12(4):283-4. PubMed ID: 21668035 [No Abstract] [Full Text] [Related]
27. Cyclosporine in psoriasis: comparison of a 25-year real-world Italian experience to current European guidelines. Altomare G; Ayala F; Bardazzi F; Bellia G; Chimenti S; Colombo D; Flori ML; Girolomoni G; Micali G; Parodi A; Peris K; Vena GA G Ital Dermatol Venereol; 2016 Aug; 151(4):432-5. PubMed ID: 25786483 [TBL] [Abstract][Full Text] [Related]
28. Methotrexate versus traditional Chinese medicine in psoriasis: a randomized, placebo-controlled trial to determine efficacy, safety and quality of life. Ho SG; Yeung CK; Chan HH Clin Exp Dermatol; 2010 Oct; 35(7):717-22. PubMed ID: 19925489 [TBL] [Abstract][Full Text] [Related]
30. The role of biologics in the treatment of moderate-to-severe plaque psoriasis. Puig L G Ital Dermatol Venereol; 2017 Feb; 152(1):28-35. PubMed ID: 27627100 [TBL] [Abstract][Full Text] [Related]
31. [Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group]. Sánchez-Regaña M; Dilmé E; Puig L; Bordas X; Carrascosa JM; Ferran M; Herranz P; García-Bustinduy M; López Estebaranz JL; Alsina M; Rodríguez MA; Ribera M; Fernández-López E; Moreno JC; Belinchón Romero I; Vidal D; Actas Dermosifiliogr; 2010 Mar; 101(2):156-63. PubMed ID: 20223158 [TBL] [Abstract][Full Text] [Related]
32. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. Asgari MM; Ray GT; Geier JL; Quesenberry CP J Am Acad Dermatol; 2017 Apr; 76(4):632-638. PubMed ID: 28162854 [TBL] [Abstract][Full Text] [Related]
33. Psoriasis of the face and flexures. van de Kerkhof PC; Murphy GM; Austad J; Ljungberg A; Cambazard F; Duvold LB J Dermatolog Treat; 2007; 18(6):351-60. PubMed ID: 17907013 [TBL] [Abstract][Full Text] [Related]
36. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals. Kerdel F; Zaiac M Dermatol Ther; 2015; 28(6):390-403. PubMed ID: 26258910 [TBL] [Abstract][Full Text] [Related]
37. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Balasubramaniam P; Stevenson O; Berth-Jones J Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371 [TBL] [Abstract][Full Text] [Related]
38. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. Gan EY; Chong WS; Tey HL BioDrugs; 2013 Aug; 27(4):359-73. PubMed ID: 23580094 [TBL] [Abstract][Full Text] [Related]
39. Drug delivery and formulations for the topical treatment of psoriasis. Su YH; Fang JY Expert Opin Drug Deliv; 2008 Feb; 5(2):235-49. PubMed ID: 18248321 [TBL] [Abstract][Full Text] [Related]